20/05/2019 21:05:00

Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%

LAKE FOREST, Ill., May 20, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for Azelastine Hydrochloride Nasal Spray, 0.1%.

According to IQVIA, U.S. sales of Azelastine Hydrochloride Nasal Spray, 0.1% were approximately $46 million for the twelve months ended March 2019.

Azelastine Hydrochloride Nasal Spray, 0.1% is indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older, and for the treatment of the symptoms of vasomotor rhinitis in adults and adolescent patients 12 years and older.

About Akorn

Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland and Paonta Sahib, India that manufacture ophthalmic, injectable and specialty sterile and non-sterile pharmaceuticals. Additional information is available on Akorn’s website at www.akorn.com.

Investors/Media:

(847) 279-6162

Investor.relations@akorn.com

AkornLogoSOLID_.jpg

Related content
30 May - 
Akorn to Present at the Jefferies 2019 Global Healthcar..
20 May - 
Akorn to Present at the RBC Capital Markets Healthcare ..
07 May - 
Akorn Provides Preliminary First Quarter 2019 Results a..
Related debate
08 May - 
nu har jeg brugt lidt tid på selskabet, de melder om st..
08 May - 
har desværre ikke så mange, men omsætningeen steg jo be..
08 May - 
hold da, godt nok var ders regnskab i går rigtig godt m..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
MODERN HEALTHCARE RECOGNIZES NEVADA LEADER AS ONE OF THE NATION’S 50 MOST INFLUENTIAL U.S. CLINICAL EXECUTIVES
2
Establishment Labs Announces Additional Financing and Improved Terms with Amendment to Existing Credit Agreement
3
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Zuora, Inc.
4
LEAD PLAINTIFF DEADLINES for INVVY, JMIA, MOMO and AAC:  Hagens Berman Reminds INVVY, JMIA, MOMO and AAC Investors of Upcoming Lead Plaintiff Deadlines
5
Nevada Copper Announces AGM Results; Remains on Schedule to Enter Production Q4, 2019

Related stock quotes

Akorn Inc 4.405 1.5% Stock price increasing

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
18 June 2019 20:44:20
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB2 - 2019-06-18 21:44:20 - 2019-06-18 20:44:20 - 1000 - Website: OKAY